Pharmaceutical companies such as BMS, Gilead, and Abbvie introduced direct anti-virus (DAA) treatments, and hepatitis C opened the era of complete recovery.

Re-treatment options for a small number of patients who failed to treat also appeared this year. The goal of hepatitis C is to find "hidden patients" who have not yet been diagnosed. Experts stress that national checkups should include hepatitis C. Bruce Kreter, general manager of Global Medical, who was in charge of the development of hepatitis C treatment at Gilead, and Ahn Sang-hoon, a professor of gastroenterology at Yonsei University Severance Hospital, asked about the current status of hepatitis C screening at home and abroad.

¡